Curriculum Vitae - Tift Regional Medical Center



Curriculum Vitae

Thomas J. Smith, M.D., F.A.C.P.

1. Personal Information

1. Name: Thomas J. Smith, M.D., F.A.C.P.

2. Born Cuyahoga Falls, Ohio, U.S.A. September 19, 1952

3. Citizenship: USA

4. Marital Status: Married, Joann Norma Bodurtha, M.D., MPH; Associate Professor of Human Genetics, Pediatrics, and Obstetrics/Gynecology

1. Children: Anna Jo Bodurtha Smith, born July 14, 1988

5. Home Address: 14219 Hickory Oaks Lane, Ashland, Virginia 23005,

(804)-798-5730

6. Business Address: Medical College of Virginia at Virginia Commonwealth University, Division of Hematology, 1101 East Marshall Street, PO Box 980230, Richmond, VA 23298-0230. E mail tsmith@hsc.vcu.edu

2. Licensure

1. Virginia 0101037893

2. DEA AS2593312

3. NCI Investigator No. 09961

4. ACLS Provider April 2001-3

1. Board Certification

2. ELNEC Certification, July 24-27, 2007

3. Hospice and Palliative Care Medicine, February 2003-2013.

4. Advanced Cardiac Life Support Provider Renewal, Center for Trauma and Critical Care, April 7, 2001

5. Hematology, 1990-2000

6. Medical Oncology, 1987-

7. Internal Medicine, 1982-

3. Education

1. Medical College of Virginia-Virginia Commonwealth University Fellowship in Hematology/Oncology 1982- 1987, Board certified in 1987; 1990.

2. Special Visiting Fellow, National Cancer Center Biological Response Modifiers Program, Frederick, MD 1986

3. Yale University School of Medicine, M.D. cum laude 1974-79

4. Yale University School of Organization and Management (core curriculum)1977-78

5. University of Akron, B.S., summa cum laude 1971-74

6. Ohio Governor's School, Fellowship in Management 1971

4. Military Service Record: None

5. Postdoctoral Training

1. Faculty Scholar, Program on Death in America, Open Society, New York 1995-9

2. Special Fellow in Medical Oncology, National Cancer Institute, NCI-BRMP, Frederick, MD 1986

3. Fellow in Hematology/Oncology, Medical College of Virginia, Richmond, VA 1984-89

1. Residency in Medicine, Hospital of the University of Pennsylvania, Philadelphia, PA, 1979-82

6. Academic Appointments or Other Significant Work Experience

1. 2002- Esteemed Professor of Medicine (oncology), VCU

2. 2001-5 Institute of Medicine National Cancer Policy Board

3. 1999- Chair, Division of Hematology/Oncology

4. 1999- Clinical Oncology Services Committee, MCVH

5. 1999- Professor, Medicine and Health Administration

6. 1999- Medical Director, Thomas Hospice Palliative Care Unit, MCVH

7. 1998 Clinical Practice Guidelines Committee Panel, MCVH

8. 1998- Advisory Board, Thomas Hospice/Palliative Care Unit at MCVH

9. 1997- Group Leader, Albert Schweitzer Institute for the Humanities, Continuing Medical Education in Kyrgyzstan

10. 1997- MCVH Hospice Working Group Leader

11. 1995-9 Associate Professor of Medicine and Health Administration

12. 1995- Physician, Cross-Over Health Ministry, Richmond, Virginia

13. 1995-8 Chairman, American Society of Clinical Oncology Health Service Research Committee; $250,000 annual budget.

14. 1995-7 Vice-Chair, Cancer and Leukemia Group B Economics and Outcomes Research Subcommittee

15. 1994-7 MCV Hospitals/Mercer Management Corporation Re-engineering Project. Charged with reducing oncology pharmacy costs by 20% in 3 years

16. 1992- Director of Cancer Education, Massey Cancer Center

17. 1992- Associate Member, Williamson Institute of Health Economics

18. 1990- Assistant Professor of Medicine & Health Administration

7. Membership - Scientific, Honorary and Professional Societies

1. Member, ASCO Cost of Cancer Care Task Force, August 2007-

2. Member, ASCPRO “Assessing the symptoms of cancer using patient related outcomes” Advisory Panel to the FDA, Charles Cleeland, PI

3. National Cancer Institute of Canada's Health Economics, Services, Policy, and Ethics (HESPE) Cancer Research Centre Planning Committee, April 2007-

4. ASCO Quality Oncology Practice Initiative Best Practices Work Group 2006-

5. Reviewer, Belgian Cancer Society, 2006-

6. RAND Technical Panel, Quality Measures at end of life, Karl Lorenz, PI, 2006-

7. MGH-Partners Technical Advisory Panel for End of Life benchmarks, Jennifer Hass MD, PI, 2006-

8. Chair, American Society of Clinical Oncology Expert Panel, White Cell Growth Factors, 2005-6.

9. Member, American Society of Clinical Oncology Expert Panel, Breast Cancer Surveillance, 2005-6.

10. Chair, National Quality Forum Project on Hospital Guidelines for Symptom Management and End of Life Care, 2004-.

11. National Consensus Project Advisory Council Project on Quality Palliative Care: Essential Elements and Best Practices 2002-4

12. External Reviewer, NCI CanCORS cancer surveillance program, 2002-6

13. American Society of Clinical Oncology Program Committee 2001-3

14. National Marrow Donor Program Optimal Size Registry Analysis Expert Panel 2000-5

15. American Cancer Society Grant Review Committee 2001-5

16. American Society of Clinical Oncology

1. Member (with RAND, Komen Foundation, Harvard School of Public Health) National Initiative on Cancer Care Quality 1999-

2. Chairman, Committee on Health Service Research 1994-98

3. Committee for Health Service Research - 1999-01

17. Board of Editors, Journal of Clinical Oncology - 1995-98

18. Co-chair, Guidelines Review Panel on use of hematopoeitic growth factors - 1998-00

19. Director, ASCO Curriculum on Palliative Care, 1999-

20. Member, ASCO Working Group on Guidelines Evaluation

21. Member, Expert Panel on Use of Tamoxifen/Raloxifene for Breast Cancer Prevention 1999

22. Member, Task Force on Improving Care at the End of Life

23. Member, Task Force on Managed Care

24. Member, Expert Panel to Determine Outcomes that Justify Cancer Treatment

25. Member, Expert Panel on Hematopoietic Growth Factors

26. Member, Expert Panel on Non Small Cell Lung Cancer Treat

27. Member, Expert Panel on Breast Cancer follow up care

28. Member, Expert Panel on Colorectal Cancer follow up care

29. Member, Expert Panel on Tumor Markers

30. Member, Expert Panel on Unresectable Prostate Cancer Care

31. Editor, Colorectal Cancer Follow up Care Guidelines

32. American Medical Association

33. Fellow, American College of Physicians

34. American Association for the Advancement of Science

35. Virginia Society of Hematology/Oncology, President, 1989-90

36. Virginia Hematology/Oncology Association 1994-

37. American Association for Cancer Education 1986-92

38. Cancer and Leukemia Group B

39. Vice-Chairman, Economics Committee - 1997 -2000

40. Liason, Leukemia Committee - 1998-01

41. National Surgical Adjuvant Breast and Bowel Cancer Program

42. American Society for Blood and Marrow Transplantation

43. European Society for Medical Oncology 1998-

44. Multinational Association for the Study of Supportive Care in Cancer

8. Membership in Community Organizations

1. 2007- Member, Chris Desch Foundation Board

2. 2004- Ashland Friends of the Library Board

3. 2000- Salvation Army Boys and Girls Clubs Camp Happyland summer camp physicals

4. 1995-99 Board of Directors, American Cancer Society, Hanover County Unit

5. 1994- Physician, Cross-Over Free Health Clinic, Richmond, VA

6. 1994- Director of Cancer Palliative Care Programs, American Medical Teams for Africa, World Health Organization/American Medical Teams for Africa Cancer Pain Relief Programme, Tanzania-Zanzibar

7. 1991-2 Childrens Story Hour Reader, Pamunkey Regional Library, Hanover County

8. 1985-7 Co-coordinator, Ashland Mountain of Trash (community cleanup and recycling)

9. 1984- Richmond Friends Meeting, Richmond, VA

9. Special Awards, Fellowships, and Other Honors

1. Oncology Nursing Society Grant to teach End of Life Care Nursing Education Consortium (ELNEC) course, Dar es Salaam, Tanzania July 2007

2. ASCO IDEA Mentor for Developing Countries, Dr. Sani Malani, Nigeria, June 2007

3. ASCO Annual Prostate Cancer Meeting Special Lecture: “Can we afford our progress?” February 24, 2007

4. Co-Chair, Supportive Care Congress, NYC February 23-5, 2007

5. MacMillan Fund UK Plenary Lecturer: NCRI Annual Conference, Birmingham, UK October 7, 2006.

6. Dutch Cancer Society External Grant Reviewer, 2006.

7. Chair, ASCO Annual Meeting, Clinical Problems in Oncology Session “Getting savvy with opioids to manage cancer pain: routes, rotations, interventions.” June 2006

8. Project ASSIST, RAND Corporation, 2006-

9. Project DeCIDE, Technical Advisory Panel for End-of-Life Benchmarks, MGH-Partners, 2006-

10. VCU Outstanding Teacher Award, Hematology/Oncology M-2 course, August 2006

11. Jonathon Gold “Humanism in Medicine” Charter Club, 2006

12. International Association of Hospice and Palliative Care University Award to best university based palliative care program 2006

13. Faculty Award for Distinguished Clinical Care, VCU Medical Center Department of Medicine 2006

14. American Hospital Association “Circle of Life” award to best hospital based palliative care program

15. Master Trainer, EPEC-O for oncologists 2005-

16. Top Doctors in America: Oncology 2001-7

17. “Top doctors in Richmond: Oncology” Richmond Magazine, Richmond Academy of Medicine 2001-6

18. “America’s Top Doctors: Medical Oncology,” Castle Connelly 2001-7

19. Outstanding Teacher Certificate, M-II course, 2002-3, awarded October 2003.

20. John Eric Olson MD Visiting Lecturer and Professor, Bassett Health Care Cancer Center, Cooperstown, New York, April 17-8, 2003

21. Dale O. Ham MD Visiting Professor, Case Western Reserve University Ireland Cancer Center, Cleveland Ohio February 7, 2003

22. Alpha Omega Alpha Medical Honor Society, Brown Sequard Chapter, May 2002.

23. “National Top Breast Cancer Doctors” Redbook Magazine, September 2001.

24. Salvation Army Boys and Girls Clubs Community Outreach Award, 2001

25. Best Doctors in Richmond: “Top medical specialists for women: breast cancer, breast diseases” Richmond Magazine, 2001

26. MCV-VCU “Distinguished Clinician Award” as the outstanding clinician in practice at the medical center. May 13, 2000

27. Best Doctors in Richmond, “Oncology”, Richmond Magazine 2000

28. National “Humanism in Medicine Award” for “embodying compassion and sensitivity in the delivery of care to patients and their family members.” May 13, 2000. New Jersey Health Care Foundation.

29. “Pioneer in Palliative Care” program designee, Robert Wood Johnson Foundation and Milbank Memorial Fund, 2000-2001.

30. Best Physicians in Richmond, Virginia (Oncology), Richmond Magazine, 1999

1. Jessie Ball duPont Fund Making a Difference Award for “creation of a program which meets a critical societal need” (Rural Cancer Outreach Program) 1996

2. Sharon H. Kohlenberg Health care Service Award, for “commitment to the fight against breast cancer”, Virginia Breast Cancer Foundation, 1995

3. Scholarship Award in Patient-Physician Communications, Department of Human Genetics, Medical College of Virginia (used patent royalties to create this endowment)

4. Fellow, American College of Physicians, 1992

5. Outstanding Alumni, Chippewa Local High School, Doylestown, Ohio, 1992

6. Outstanding Paper (Dr. Bruce Hillner, coauthor), Society of Medical Decision-Making, 1991

7. Best Teacher, Department of Internal Medicine, 1989.

31. Fellowships

1. Visiting Professor in Palliative Care and Oncology, McGill University/University of Montreal/ Institute for Clinical Research, Montreal, Quebec, Canada, November 1998

2. Pfizer Traveling Fellowship Award, Clinical Research Institute of Montreal, Montreal, P.Q. March 1996

32. External Grants

1. NLM GO8 (RO1) Smith T (PI), with Khatcheressian J, Lyckholm L, Matsuyama R; consultants Crawford J, Siminoff L, Schrag D, Loprinzi C, Tannock I. Provision of honest, accurate helpful information on the Internet for patients about prognosis, treatment efficacy, and treatment decisions of breast, colorectal, lung, and prostate cancer. Goal: improve cancer treatment decisions in cancer patients by provision of honest information about prognosis, treatment options, treatment efficacy and side effects. Role: PI. 20% effort and salary

2. R01CA116227-01 (Meier). Morrison S, Meier D, Smith T, et al. (9/29/06 approved for funding ; 5 years) Impact of palliative care on outcomes of hospitalized patients. Six center study; site PI. Goal: assess the impact of palliative care consultation on health and economic outcomes of hospitalized sick inpatients at 6 major hospitals. Role: Site PI. 10% effort and salary.

3. JEHT Foundation, New York, New York. Continuation grant for CAPC Palliative Care Leadership Center, $375,000/3 years (to match other program funding.)

4. Robert Wood Johnson/Center to Advance Palliative Care National Center of Excellence for Palliative Care Education, 7/1/03-6/31/06. $750,000. 20% effort and salary.

5. American Cancer Society. Targeted Cost-Effectiveness Assessments in Cancer. PI Hillner BE. 01/01/04 to 12/31/07, 2.5% effort/salary, $143,125

6. Commonwealth of Virginia. Virginia Initiative for Palliative Care (VIPC). 11/05-present. $100,000/year. Train Virginia health care professionals in palliative care.

7. The goal is to provide objective, non-commercial CEA’s for high cost technology, such as monoclonal antibody therapy.

8. VistaCare Foundation. Randomized trial of nebulized fentanyl vs placebo for dyspnea. PI, Tom Smith. $10,000. 7.1. 03, one year.

9. American Cancer Society, Targeted Cost effectiveness Assessments in Cancer Treatments. Bruce Hillner, PI; Tom Smith, Investigator, 2.5%, 1.1.04 to 12.31.07.

10. 2002-5 NCI Core Grant for Massey Cancer Center: co-leader, Cancer Control, 10% time and effort Source: NIH/NCI Grant Number: 5 P30 CA16059-20 $586,494 Period of Support: 6/01/02 - 06/01/07

11. 1999-3 Principal Investigator. AA randomized clinical trial to evaluate the effectiveness, cost-effectiveness, and impact on quality of life of implantable narcotic delivery systems vs. best standardized pain control.” Medtronic, Inc. Minneapolis, MN. Medtronics, Inc. Minneapolis, MN. ~20% salary and time.

12. 1999 Principal Investigator, with Dr. Roger Winn, M.D. Anderson Cancer Center, Houston, Texas. Managed Care Organization Survey, for American Society of Clinical Oncology. $6977.

13. 1999 - Hunton Foundation, Richmond, Virginia. $7,000. Education Center for hospice.

14. 1998-9 Principal Investigator, with Bruce E. Hillner. Assessing the quality of cancer care in the United States.” Report to the Institute of Medicine and National Cancer Advisory Board. 25% effort. (Continued consultations)

15. 1998 Principal Investigator. Randomized clinical trial of implantable narcotic delivery systems”. Medtronics, Inc. Minneapolis, MN. $20,000. Design of clinical trial.

16. 1998-1 Principal Investigator. Creation of a Palliative Care Unit to Serve the Medically Under-served”. Jessie Ball DuPont Fund, Jacksonville, Florida, $287,000/3 years.

17. 1998-01 Consultant, Economic evaluation of CALGB 9343, K. A. Schulman, MD, PI, Georgetown University.

18. 1996-8 Principal Investigator: CALGB 9411, Economic Evaluation of filgrastim (G-CSF) versus placebo during remission, induction, and consolidation for Adult Lymphoblastic Leukemia. Contract under negotiation; 10% effort and salary; $108,000. Unrestricted research grant from CALGB Foundation.

19. 1997- Consultant, R-25, PI-Peter Raich, MD, AMC Cancer Center, Denver, CO. The impact of easy to read consent statements on clinical trials”. Eastern Cooperative Oncology Group, North Central Cancer Treatment Group. 2-4 days/year.

20. 1996-7 Consultant. PI-Ian Tannock, MD PhD, Ontario Cancer Institute. Economic analysis of NOV.22 (Phase 3 trial of mitoxantrone plus low dose prednisone versus low dose prednisone for symptomatic hormone-resistant prostate cancer. $1,000/year.

21. 1996-7 Consultant.PI-Bruce E. Hillner, MD. Pharmacoeconomic analysis of ECOG adjuvant interferon melanoma trial. $5,000/year.

22. 1995-8 Principal Investigator. Open Society, New York. Faculty Scholar, Death in America Project. 60% effort and salary. Begins July 1, 1995.

23. 1995-8 Principal Investigator/Mentor. Fellowship in Supportive Care and Pharmacoeconomics. SmithKlineBeacham unrestricted grant. $54,000/year. 0% support.

24. 1995-6 Co-Investigator. Cancer and Leukemia Group B 9570. Project to establish standard method for incorporating economic evaluation within cancer clinical trials. 0% support.

25. 1995-8 Co-Principal Investigator. “Effect of case management alternatives on the satisfaction, quality of life, and cost of care for metastatic nonsmall cell lung cancer patients.” Williamson Institute for Health Economics, VCU-MCV, Richmond, VA. 10% salary and support, begins July 1, 1995.

26. 1994-5 Principal Investigator: "Economic evaluation of GCSF92106: Randomized clinical trial of filgrastim mobilizes peripheral blood progenitor cell transplantation in comparison with autologous bone marrow transplantation in patients with Hodgkins disease and non-Hodgkins lymphoma." $107,000 total; 20% effort and salary. Unrestricted research contract with AMGEN, Thousand Oaks, CA.

27. 1993-8 Co-principal investigator, with Dr. Peter Raich. RFP No. CO-33004-63. West Virginia, Virginia, and Ohio Cancer Information Service, Office of Cancer Communications, NCI. Massey Cancer Center Subcontract $464,259/5 years. Effective 6/30/93. 5% effort, salary support not included per contract stipulation.

28. 1993-5 Co-Principal Investigator. "Economic Analysis of Chemotherapy for Non-Small cell Lung Cancer." Burroughs Wellcome Epidemiology, Surveillance, and Pharmacoeconomics Section, Research Triangle Park, N. C. 20% effort and salary; $85,000 total.

29. 1993-4 Co-Principal Investigator. "Economic Analysis of Rural Cancer Outreach Programs" Jessie Ball duPont Fund, Jacksonville, Florida. $50,000/1 year.

30. 1992-5 Career Development Award: "Building models for rational and equitable distribution of cancer care resources: the use of decision analysis to evaluate efficacy and cost-effectiveness of therapy." American Cancer Society. Funded 7/1/92. 25% effort, 25% salary; $90,000 total/3 years.

31. 1991-3 Co-Investigator. "Evaluation of Practice Variations and Costs for Cancer", with Sheldon Retchin, MD, MSPH. Agency for Health Care Policy and Research. 10% effort, 10% salary.

32. 1990-2 Principal investigator. "Community Home Health Care for Cancer Patients: Meeting the Needs of Cancer Patients and their Families in Underserved Areas". Jessie Ball duPont Religious, Charitable, and Educational Trust Fund. $170,000/3 years.

33. 1991-3 Principal Investigator. A Pilot Study of Cancer Treatment Combining Histamine and Histamine2 Receptor Antagonists. Supported by Glaxo Pharmaceuticals, Research Triangle Park, N.C. $62,300/year.

33. Grant Support, pending

34. Invited Seminars (1993-present)

35. “Breast cancer palliative oncology” School of Breast Oncology, Emory University, Nove 9-11, 2007.

36. “Integrating palliative care into usual medical care” Stamford Hospital/Columbia School of Medicine Grand Rounds, November 16, 2007

37. “Can we afford the future: cost considerations in oncology” University of Vermont Keynote Speaker, ASCO Update, June 19, 2007

38. “Preventing oncologist burnout” ASCO Annual meeting Education Session, June 6 and 7, 2007

39. Special Erythropoesis Stimulating Agents Consensus Panel Member, ASCO Meeting, June 6, 2007

40. “Palliative Medicine in everyday practice” EVMS/Sentara Special Lecture series, May 3-4, 2007

41. ASCO Annual Prostate Cancer Meeting Special Lecture: “Can we afford our progress?” February 24, 2007

42. Co-Chair, Supportive Care Congress, NYC February 23-5, 2007. Lectures: “update in advanced pain management.” And “Defragmenting the system: ways to improve health care by coordination”

43. MacMillan Fund UK Plenary Lecturer: NCRI Annual Conference, Birmingham, UK October 7, 2006.

44. Chair, ASCO Annual Meeting, Clinical Problems in Oncology Session “Getting savvy with opioids to manage cancer pain: routes, rotations, interventions.” June 2006

1. University of Kentucky Norton Health System, July 2006: Starting Palliative Care Programs; Interventional Pain Management

2. ASCO People Living with Cancer “ask the expert” series. June 2006.

3. ASCO Special education session “Getting savvy with opioids”, June 5-6, 2006

4. Dartmouth-Hitchcock Norris Cotton Cancer Center Tranforming Cancer Care: Patients at the Center of Science and Service, New Hampshire, May 25, 2006

5. City of Hope “Barriers” Keynote Speaker, “Practical approach to managing pain and fatigue”, Duarte, CA April 13, 2006

6. Mercy Medical Center, Miami. “Creating palliative care within medicine” February 2006

7. City of Hope First Annual Mark Schaffner MD Memorial Lecture, November 1, 2005.

8. ASCO “meet the professor” session, 2005

9. Virginia Association of Hospices Keynote speaker, April 7, 2005

10. Society of Behavioral Medicine workshop leader, March 2005, Boston.

11. American Academy of Hospice and Palliative Medicine keynote speaker, March 2003, Atlanta.

12. National Supportive Care Congress, “New methods of pain control” February 25, 2005, San Francisco

13. RAM Shelton Horsely Memorial Lecture, February 2005, Richmond.

14. Hospice of Michigan/Wayne State University School of Medicine 2nd Annual Conference. “Cost effective inpatient palliative care” and “New developments in pain management”. October 8-9, 2004.

15. ASCO Meet the Professor Sessions, June 2004: “Clinical trials and cost effectiveness”, New Orleans.

16. Emory University Winship Cancer Center Keynote Address, June 2004: “Improving quality of life in supportive care and palliative care patients”

17. MASCC International Meeting, June 2004: Centers of excellence in palliative and supportive care. Miami, FL.

18. Baystate Medical Center Log Cabin Retreat, Northampton, MA, April 2004. Palliative Care.

19. DELEtECC National Meeting: “Improving care in palliative care”, City of Hope National Medical Center, Pasadena, CA, April 2004.

20. Grand Rounds: Roswell Park Cancer Institute, January 2004.

21. U. Michigan Cancer Center Grand Rounds, September 2003 “Treatment of refractory pain”

22. Karmonos Cancer Center Grand Rounds, September 2003 “Treatment of refractory pain”

23. U. Wisconsin Cancer Center Grand Rounds, June 4, 2003 “Treatment of refractory pain”

24. NCI Clinical Center Grand Rounds, “Randomized clinical trial results from the Cancer Pain Trial”, May 21, 2003

25. Olson Lecture, Bassett Health Care, Cooperstown NY, April 16, 2003.

26. “Care of the Difficult Patient – whatever that means” Disseminating End of Life Care to Cancer Centers, City of Hope, Pasedena, CA April 5, 2003.

27. “The relationship between volume and quality” Society of Surgical Oncology keynote speaker, March 6, 2003.

28. “Implantable drug delivery systems for refractory cancer pain”. Association of Northern California Oncologists, March 5, 2003

29. “The medical oncologist perspective on refractory cancer pain”. Karmonas Cancer Center, February 6, 2003

30. “The medical oncologist perspective on refractory cancer pain”. U Pitt Medical Center, February 5, 2003

31. “Clinical trials in advanced cancer pain management” M.D. Anderson Cancer Center, January 7, 2003

32. “Implantable drug delivery systems for refractory cancer pain”. Duke University Medical Center/Cancer Center Anesthesia Grand Rounds, December 4, 2002

33. “Implantable drug delivery systems for refractory cancer pain”. Memorial Sloan Kettering Cancer Center, November 2002; Pain and Palliative Care Grand Rounds

34. Multinational Association for Supportive Care in Cancer (MASCC), “Intrathecal opioids: review of the evidence” Boston, MA June 26, 2002.

35. American Alliance of Cancer Pain Initiatives Keynote Speaker: “Cancer pain management in the new economy” June 14, 2002, Richmond, VA.

36. ASCO Industry Sponsored Symposium, Chair. “Advances in Pain Management” May 17, 2002

37. ASCO Education Session, Annual meeting, May 18, 2002: Follow up care of the patient with breast and lung cancer.

38. VCU-MCV International Cancer Rehabilitation Conference, Richmond, VA October 20, 2001 “Care of the Difficult Patient”

39. Virginia Commonwealth University Mini-Med School, Richmond, VA “Cancer Pain”

40. Association of Cancer Pain Initiatives Keynote Speaker, June 2001; Madison, WI.

41. American Society of Clinical Oncology: Program Chairman, Symposium on Supportive Care and Symptom Control. May 11, 2001

42. American Society of Clinical Oncology: Using quality to survive Managed Care. Care. May 11, 2001

43. Medical Group Management Association: Quality assessment in clinical practice. San Antonio, April 2001.

44. Iceland Cancer Hospital: Rekjavik, “Improving cancer care”, March 2001

45. American Society of Clinical Oncology: Symposium on Practice Management. AHow to maximize patient services” May 11, 2001

46. “Technology at end of life” The end of our lives - guiding the research agenda. NIH-NINR, Bethesda, MD. November 14, 2000.

47. “Outcomes research” Swiss Society for Clinical Research, Lucerne, Switzerland, June 22, 2000

48. American Society of Clinical Oncology: Program Chairman, Symposium on Supportive Care. May 19, 2000

49. American Society of Clinical Oncology: Program Chairman, Symposium on Supportive Care. “Improving Communications with Written treatment plans.” May 19, 2000

50. American Society of Clinical Oncology “Meet the Professor” session on Outcomes Research, May 1999

51. American Society of Clinical Oncology Education Plenary Session, “Economic and clinical consequences of CSF Use” May 1999

52. University of Kentucky at Lexington, Effectiveness and cost-effectiveness of high dose chemotherapy: practice, evidence, and politics. April 17, 1999.

53. Hematology/Oncology Grand Rounds, Massachusetts General Hospital, February 19,1999, Boston MA.

54. Medical Grand Rounds, (Improving Quality in Medical Care); Geriatric Grand Rounds, (Supportive Care); combined geriatric and oncology fellows conference (advanced supportive care and chemotherapy), Mt. Sinai School of Medicine, New York, January 5, 1999

55. Oncology Grand Rounds, McGill University Royal Victoria Hospital ‘Can we improve the quality of cancer care?” November 4, 1998; also, Oncology Research Conference at McGill “Better care, less cost, satisfied patients”; also, Grand Rounds, Montreal General Hospital “Putting health service to work in palliative care: ways to improve care and save money” November 5, 1998

56. “Economics of cancer treatment and care”, National Cancer Survivors Network Meeting: Atlantic City, N.J., October 8, 1998

57. “Breast cancer follow up strategies”, MCV-VCU Cancer Conference, Richmond VA October 10, 1998

58. “Improving doctor and patient communication”, Virginia Department of Health Annual Breast cancer Conference, October 5, 1998

59. “Clinical and economic aspects of hematopoetic growth factor use”, Princess Margaret Hospital/ Ontario Cancer Research and Treatment Foundation, September 26, 1998.

60. “Clinical and economic aspects of growth factor use”, Atlanta, GA, September 18, 1998.

61. Visiting Professor, McGill University and University of Montreal, November 1998

62. “The usefulness of Utility” 1st Annual NIH Research in Palliative Care Conference, Bethesda MD May 7-9, 1998

63. “The ethics of cost constraint in oncology” Mont Marie Ethics Symposium, Holyoke, MA April 26-27, 1998

64. “Lung cancer” and “Update in Hematology” National Cancer Information Exchange (CIS) Amelia Island, Florida, February 13-15, 1998

65. “Cost savings and quality improvement in oncology” Cancer Center/Medicine Grand Rounds, Washington Hospital Center, Washington, D.C. January 16, 1998

66. “Palliative Care” Columbia University College of Physicians and Surgeons Harlem Hospital Medical Grand Rounds, New York, New York, January 7, 1998

67. “Economic analysis of hematopoietic growth factors” European Organization for Research and Treatment of Cancer, Brussels, Belgium, November 17, 1997

68. “Research in quality of life and economics for palliative care” Japanese Intractable Disease Society Tokyo, Japan, October 29-30, 1997.

69. “Ethics in health care rationing” Australian Society for Chemotherapy, Sydney, June 30, 1997.

70. “End of Life Management of the cancer patient: emerging problems for the oncologist” Plenary Session, American Society of Clinical Oncology, Denver CO, May 18, 1997

71. “Economic analysis of end of life care” Education Session, American Society of Clinical Oncology, Denver CO, May 18 and 19, 1997

72. “Determining prognosis in the incurable patient: how to choose between aggressive, palliative and hospice care” 2nd Annual Cancer Information Exchange for Primary Care Providers, Amelia Island, Florida, February 14, 1996

73. “Surveillance testing in curatively treated cancer survivors” American Society of Clinical Oncology Fall Education Meeting, November 8, 1996, Phoenix, AR.

74. “Principles of Health Care Economics”. Hamilton Regional Cancer Center, McMaster University, Economics of Health Care in Oncology Symposium, October 7-8, 1996.

75. “Quality of life yardsticks: are they useful?” and ACan the health care system afford the knowledge we are gaining?” Eighth International Symposium on Supportive Care in Cancer, Toronto, June 20-22, 1996

76. “Crabs on the Medical Commons: comparing cost-effectiveness of cancer, AIDS, and cardiology care” Medical Grand Rounds, Ohio State University, Columbus Ohio June 6, 1996.

77. “Evaluating health care plans and providers: use of disease-specific report cards based on Blue Cross/Blue Shield data” James Cancer Center Grand Round, Ohio State University, Columbus Ohio, June 6, 1996.

78. “Clinical outcomes and costs of cancer treatment: can we afford the advances we are making?” American Society of Clinical Oncology Educational Meeting, Philadelphia, May 18, 1996

79. “Cost-effectiveness of cancer care”. The Cancer Foundation Celebration 1996, Hogsby, Sweden, March 22, 1996.

80. “Cost of high dose chemotherapy and stem cell replacement: provider, patient, and insurer perspectives” Workshop leader, Blood Cell and Bone Marrow Transplant Symposium, Keystone, CO, January 15, 1996.

81. “Cost control in cancer”. Medical Grand Rounds, Winthrop University Hospital, SUNY, Mineola, NY, December 13, 1995

82. “Pain control in Extremes of Age: children and old adults” Symposium on Pain Management: Attitudes, Obstacles, and Issues. Senate Joint Subcommittee, Richmond, VA December 6, 1995

83. “Cost-effective of breast cancer treatments - compared to alternative uses of the same dollars” Ontario Cancer Institute, Toronto, Ontario; Hamilton Regional Cancer Treatment Center, Hamilton; London Regional Cancer Treatment Center, London. October 3-5, 1995.

84. “Alternative Methods to Assess Outcomes in High Dose Chemotherapy” American Society for Blood and Marrow Transplantation, Milwaukee Wisconsin July 27, 1995

85. “Pharmacoeconomics and High Tech High Cost Care: Practice Guidelines in U.S. and Canada.” Quebec Society of Hematology and Oncology, Val Morin, Province Quebec, May 31, 1995

86. "Strategic Alliances of Cancer Care Providers: One Solution to Increasing Access and Lowering Costs of Cancer Treatment." W.H.O. Conference on Palliative Care, Ulm, Germany, March 13-15, 1995

87. "Studies of Economic Outcomes of Cancer Treatment", 1995 Quality of Life Symposium: Quality of Life and Economic Outcomes in Cancer Care: a New Focus for Healthcare Providers, Payers, and Policymakers. Long Beach, CA March 4-5, 1995

88. "Cost effectiveness of bone marrow transplantation: American Society for Blood and Marrow Transplantation, Keystone, Colorado, January 26, 1995

89. "Meta-analysis Techniques/Outcomes Research" National Autologous Bone Marrow Transplant Registry Annual Meeting, Keystone, CO, January 23, 1995

90. "Evaluating New Technologies: the Case of Autologous Bone Marrow Transplantation for Breast Cancer" National Blue Cross Blue Shield Directors Meeting, Chicago, June 27, 1994

91. "Oncology Care Delivery in the Reformed Health Care System" Bios Communications, New York, June 24-25, 1994

92. "Cost Effectiveness of Palliative Care for Cancer", German Cancer Conference, March 11, 1994, Hamburg, Germany.

93. "Cost Effectiveness of High Dose Chemotherapy for Breast Cancer" May 1994; American Society of Clinical Oncology Educational Session. With Drs. Karen Antman and Robert Livingstone.

94. "Effectiveness and cost effectiveness of adjuvant chemotherapy for breast cancer." Tottori University School of Medicine, Yonago Japan, November 22, 1993

45. Other

1. Patents

2. Co-patentee. "Treatment and prevention of oral mucositis with growth factors". Triton Biosciences, Alameda, CA. Patent 5102870, April 7, 1992;

3. European Patent Office No: 90903469.6-, filed October 30, 1991; the Hague.

10. Major Committees

1. University/Hospital

1. Chair, Oncology Services Committee - 1999-

2. Chair, MCVH Oncology Pharmacy and Therapeutics Committee

3. Promotion and Tenure Committee, Dr. Richard Seither, 1998-99

4. Promotion and Tenure Committee, Dr. Brian Kavanagh, 1998-99

5. MCVH Pharmacy and Therapeutics Committee

6. VCU-MCV Curriculum Revision Committee

7. VCU-MCV M-II Hematology Curriculum Committee

8. 1997-98 MCV-VCU Endocrinology Chair Search Committee

9. 1996-8 MCVH Pharmacy Chair Search Committee

10. MCVH Pharmacy Quality Control Standards for Anti-neoplastic Drugs Committee

11. VCU-MCVH Patient Education Council

2. Professional

1. National Study Section: 1996-01 American Cancer Society, Atlanta GA. Psychosocial, Behavioral, and Policy Research.

2. Boards

1. Editorial Boards (all until present unless noted)

2. 1999 - Editorial Board, Journal of Palliative Medicine

3. 1998- Editorial Advisory Board, Journal of Clinical Oncology, AThe Art of Oncology: When the Tumor is Not the Target”

4. 1999 - Editorial Board, Evidence-based Oncology

5. 1998- Medical Advisory Board, InTouch, The good health guide to cancer prevention and treatment, PRR, Inc.

6. 1997- Editorial Board, Journal of Palliative Medicine

7. 1994-7 Editorial Board, Oncology

8. 1995- Editorial Board: Journal of Clinical Oncology

9. 1992- Special Features Editor, Clinical Oncology Alert

10. 1992- Editorial Advisory Board, Oncology News International

11. 1998- Commentator, Evidence-Based Medicine

12. 1996- Reviewer, Psychosomatic Medicine

13. 1996- Reviewer, Annals of Cancer Control Research

14. 1996- Reviewer, PharmacoEconomics

15. 1994- Reviewer, Health Canada, Ontario, Canada

16. 1994- Reviewer, JAMA

17. 1994- Reviewer, Medical Research Council, London, Great Britain

18. 1993- Reviewer, New England Journal of Medicine

19. 1993- Reviewer, Cancer Investigation

20. 1993-Reviewer, Journal of the National Cancer Institute

21. 1993-Reviewer, Radiation Oncology Investigations

22. 1993-Reviewer, AHFS Drug Information

23. 1992-Reviewer, Cancer

24. 1991-Reviewer, Journal of Clinical Oncology

25. 1988-Reviewer, Cancer Research

3. Councils

1. NIH-NCI Lung Cancer Progress Group, 2001

2. Institute of Medicine/National Academy of Sciences. Enhancing Data Systems to Improve the Quality of Cancer Care. October 4-6, 1999.

3. National Marrow Donor Program (NMDP) Registry Size Analysis Review Panel 1998-2002

4. NIH Conference on Research in Palliative Care Planning Committee, 1999 - 00

5. The March for Cancer, Basic Science and Research Planning Group, Washington, D.C., October 1998 (report issued November 1998)

6. NIH Conference on Research in Palliative Care Planning Committee, 1998-2000

7. Planning Group, Institute for Healthcare Improvement, Breakthrough Series on Improving Care at the End of Life. Boston, MA

8. Member, ASCO Panel on Cancer Care at the End of Life, Lowell E. Schipper, MD, Chair

9. Peer reviewer, Virginia Health Quality Center, Richmond VA, 1996

10. Regional Quality Council Specialty Advisory Panel, CIGNA, 1996

11. Advisory Panel, Center for Health Policy Studies, ACancer Information for Low- literacy Women”, Columbia MD, 1996

12. Steering Committee, American Society of Clinical Oncology Technology Assessment of High Dose Chemotherapy with Stem Cell Support, 1994

13. American Society of Clinical Oncology Technology Assessment Committee

14. Organizing Committee, American Society of Clinical Oncology Outcomes Research Work Group

15. Agency for Health Care Policy and Research (AHCPR) Review Group on Guidelines for Cancer Pain Management, 1992

16. American Society for Clinical Oncology Working Group on Technology Assessment; Ad Hoc Committee for Development of Guidelines for the Use of Hematopoietic Growth Factors, 1992

11. Other significant scholoarly, research, or administrative experience

1. Graduate students trained

2. Post-doctoral trainees

1. Dr. David Bloomfield, Oncology Fellow, Princess Margaret Hospital, Toronto, Ontario Canade, thesis co-advisor/consultant with Ian Tannock, published in Journal of Clinical Oncology 1998

2. Dr. Simona Milanese, supervised her analysis of a completed randomized clinical trial, published in Eur J Cancer

3. Dr. David Robinson, supervised his design of a Markov Model to evaluate effectiveness and cost effectiveness of interferon-alpha vs bone marrow transplantation for chronic myelogenous leukemia. Not published.

4. Post doctoral fellowship: Robin Matsuyama PhD, 2005-6

5. Pre doctoral student: Kristie Stover, 2004-5. PhD December 2005.

3. Major Teaching Assignments (all continuous unless specified)

1. 1996 - MII Hematology Course: Ethics and end of life care; medical care of the ding patient; Plasma cell disorders and leukemias

2. 1995 - Health Administration Seminar: Health Systems Analysis and Evaluation Methods; Longtitudinal study designs; cost analysis

3. 1993 - Health Administration 763 (doctoral level course): cost-effectiveness analysis; policy analysis based on outcomes

4. 1991 - 6 M-IV Elective #8892. "Cancer Care in Rural Virginia."

12. Bibliography

1. Papers Published (*primary or corresponding author)

1. *Smith T, Viverette JF, Adelman BA. The Use of Antithrombotic Therapy in the Elderly. Geriatric Clinics of North America 1: 877-897, 1985.

2. *Smith T: Fatty Replacement of Lymph Nodes Mimicking Lymphoma Relapse. Cancer 68(12): 2686-2688, 1986.

3. *Smith T: Acute Tumor Lysis Syndrome Following Platelet Transfusion. Virginia Medical 113:100-101, 1986.

4. *Smith T, Clark JW, Popp MB: Regression of Tumor Nodules in a Patient Treated with Ranitidine. Archives of Internal Medicine 147(10): 1815-1816, 1987.

5. *Smith T: Tumor Lysis Syndrome after Steroid Therapy for Anaphylaxis. Southern Medical Journal 81(3):415-416, 1988.

6. *Smith T: H2 Receptor Antagonists and Cancer Immunotherapy. Comprehensive Therapy 16:8-13, 1990.

7. *Smith T, Grossberg HG: Successful Use of Granulocyte-Macrophage Colony Stimulating Factor in Patients with Acute Lymphocytic Leukemia. American Journal of Medicine 1990;89:384-386.

8. *Smith T. Editorial: Author! Author! JAMA 263:3193, 1990.

9. *Smith T, Kaplowitz LG: Treatment of Kaposi's Sarcoma in AIDS Patients with Cimetidine. JNCI 83:139-141, 1991.

10. *Smith TJ, Desch CE. Neutropenia-wise and pound-foolish: care of the massively obese chemotherapy patient. Southern Medical Journal 84:883-885, 1991.

11. Hillner BE, Smith T. Efficacy and cost-effectiveness of adjuvant chemotherapy in women with node-negative breast cancer. A decision analysis model. N Engl J Med 324:160-168, 1991.

12. Hillner BE, Smith TJ. A model of chemotherapy in node-negative breast cancer. JNCI Monographs 11:143-149, 1992.

13. *Smith T, Desch C, Simonson C, Kane N. Teaching subspecialty medicine in a rural hospital. J Cancer Education 6:1-6, 1991.

14. *Smith TJ, Desch CE, Kaplowitz LG. Pulmonary Disease in the AIDS Patients with Kaposi's sarcoma. Infections in Medicine 9(2):10-16, 1992.

15. Desch CE, Lasala MR, Smith TJ, Hillner BE. The Optimal Timing of Autologous Bone Marrow Transplantation in Hodgkin's Disease Patients Following a Chemotherapy Relapse. J Clin Oncol 10:200-209, 1992.

16. Smith TJ, Brown PA. The Cancer Information Service: What it can do for you. Indian Health Service Provider, 16(10):156-157, 1991.

17. Desch CE, Smith TJ, Briendel CA, Simonson CJ, Kane N. Cancer Treatment in Rural Areas. Hospital and Health Services Administration 37:449-463, 1992.

18. Hillner BE, Smith TJ, Desch CE. Efficacy and Cost-Effectiveness of Autologous Bone Marrow Transplantation in Metastatic Breast Cancer -- Estimates using decision analysis while awaiting clinical trial results. JAMA 267:2055-2062, 1992.

19. Brown PA, Ames N, Mettger W, Smith TJ, Gramarossa G, Friedell GH, McDonald SS. Closing the Comprehension Gap: The link between cancer and illiteracy. JNCI Monographs 14:147-156, 1993.

20. Hillner BE, Smith TJ. Should women with node-negative breast cancer receive adjuvant chemotherapy? Insights from a decision analysis model. Breast Cancer Research and Treatment 23:17-27, 1992.

21. Desch CE, Hillner BE, Smith TJ, Retchin SR. Should the elderly receive chemotherapy for node-negative breast cancer? A Cost -Effectiveness Analysis Examining Total and Active Life-Expectancy Outcomes. J Clin Oncol 11:777-782, 1993.

22. *Smith TJ, Hillner BE. The efficacy and cost-effectiveness of adjuvant therapy of early breast cancer in premenopausal women. J Clin Oncol 11:771-776, 1993.

23. Hillner BE, Smith TJ, Desch CE. Assessing the cost effectiveness analysis of adjuvant therapies in early breast cancer using a decision analysis model. Breast Cancer Research and Treatment 25:97-105, 1993.

24. *Smith TJ, Desch CE, Hillner BE. Efficacy and Cost-effectiveness in Oncology: Rational Allocation of Cancer Care Resources. JNCI 85:1460-71, 1993.

25. *Smith TJ. Which Hat Do I Wear? Discussing Costs of Breast Cancer Treatment with Patients. JAMA 270:1657-1659, 1993.

26. *Smith TJ, Desch CE, Hillner BH. Ways to reduce the cost of oncology care without compromising the quality. Cancer Investigation 12:257-265, 1994.

27. Hillner BE, Smith TJ, Desch CE. Principles of cost effectiveness analysis for the assessment of current and new therapies. J Hematherapy 2:501-506, 1993.

28. Hillner BE, Smith TJ, Desch CE. Cost-effective use of autologous bone marrow transplantation: few answers, many questions, and suggestions for future assessments. Pharmacoeconomics 6:114-126, 1994.

29. Hampton CL, Mazmanian PE, Smith TJ. Applying telecommunications technology: a case study of a videoconference to disseminate breast cancer guidelines. Journal of Continuing Education in the Professions 14:83-89, 1994.

30. ASCO Ad Hod Colony-stimulating factor Guidelines Expert Panel. American Society of Clinical Oncology Recommendations for the Use of Hematopoietic Colony-Stimulating Factors: Evidence-Based, Clinical Practice Guidelines. J Clin Oncol 12:2471-2508, 1994.

31. Hillner BE, Smith TJ. Cost effectiveness and other assessments of adjuvant therapies of early breast cancer. Oncology 1995;9(11S):129-34.

32. Franzak FJ, Smith TJ, Desch CE. Marketing cancer care to rural residents. Journal of Public Policy and Marketing 14:76-82, 1995.

33. Desch CE, Hillner BE, Smith TJ. Economic considerations in the care of lung cancer patients. Curr Opin Oncol 1996;8:126-32.

34. *Smith TJ, Hillner BE, Neighbors DN, McSorley PA, Le Chevalier T. Efficacy and cost effectiveness of chemotherapy for non-small cell lung cancer: results from a clinical trial comparing vinorelbine, vinorelbine plus cisplatin, and vinorelbine plus cisplatin. J Clin Oncol 1995;13:2166-73.

35. *Smith TJ, Penberthy L, Desch CE, Whittemore M, Newschaffer C, Hillner BE, McClish D, Retchin SM. Differences in initial treatment patterns and outcomes of lung cancer in the elderly. Lung Cancer 1995;13:235-252.

36. *Smith TJ, Bodurtha JN. Ethics in Oncology: Balancing interests of the patient, oncologist, and society. J Clin Oncol 1995;13:2464-70.

37. Bennett CL*, Smith TJ*,George SL, Hillner BE, Fleishman S, Neill B. Free Riding and the Prisoner's Dilemma:Problems in funding economic analyses of phase III cancer clinical trials J Clin Oncol, 1995;13:2457-63.

38. Smith TJ*. Decision Analysis in Oncology. Oncology, 1995;9S:37-46.

39. Desch CE, Penberthy LP, Newschaffer CJ, Hillner BE, Whittemore J, McClish D, Smith TJ, Retchin SM. Factors that determine the treatment for local and regional prostate cancer. Medical Care 1996;34:152-162.

40. Hillner BE, Desch CE, Carlson RW, Smith TJ, Esserman L, Bear H. Tradeoffs between survival and breast preservation for three initial treatments of ductal carcinoma of the breast. J Clin Oncol 1996;14:70-77.

41. American Society of Clinical Oncology Outcomes Working Group (core member, manuscript editor). Outcomes of cancer treatment for technology assessment and cancer treatment guidelines. J Clin Oncol 1996;14:671-679.

42. Desch CE, Smith TJ. Defining treatment aims and end-points in older patients with cancer. Drugs & Aging 1995;6:351-357.

43. Hillner BE, Smith TJ. Cost-effectiveness analysis of three regimens using vinorelbine (Navelbine) for non-small cell lung cancer. Seminars in Oncology 1996;23 (S):25-30.

44. Smith TJ*. Economic analysis of CSFs. Curr Opin Hemat 1996;3:175-179.

45. Teague KE, Brown JA, Meyer JM, Kahn MJK, Smith TJ, Bodurtha JN. Teaching efficacy of a medical education module on genetic testing for breast cancer. J Cancer Educ 1996;11:196-202.

46. Smith T*. Lessons in Survival. In “Caring for the Dying: Identification and promotion of physician competency.” American College of Physicians. ACP, Philadelphia, PA, 1997.

47. Hillner BE, Penberthy L, Desch CE, McDonald MK, Smith TJ, Retchin SM. Variation in staging and treatment of local and regional breast cancer in the elderly. Breast Cancer Research and Treatment 1996;40:75-86.

48. Ozer H, Miller LL, Schiffer CA, Winn RA, Smith TJ* (manuscript editor). American Society of Clinical Oncology Update of Recommendations for the Use of Hematopoietic Colony-Stimulating Factors: Evidence-Based, Clinical Practice Guidelines. J Clin Oncol 1996;14:1957-1960.

49. Hillner BE, McDonald MK, Penberthy L, Desch CE, Smith TJ, Maddox P, Glasheen WP, Retchin SM. Measuring standards of care for early breast cancer in an insured population. J Clin Oncol 1997;15:1401-1408.

50. Winn RJ, Smith TJ. The American Society of Clinical Oncology Guideline Program. Pharmacy Practice Management Quarterly 1996;16:31-38.

51. Smith TJ*, Desch CE, Grasso MA, McCue MJ, Buonaito D, Grasso K, Johantgen ME, Hackney MH, Shaw JE, Simonson CJ. The rural cancer outreach program: clinical and financial analysis of palliative and curative care for an underserved population. Cancer Treatment Reviews 1996;22S:97-101.

52. Hillner BE, Smith TJ. Cost effectiveness and other assessments of adjuvant therapies for early breast cancer. Oncology 1995;9S:129-134.

53. Desch CE, Smith TJ. Economic considerations in the care of lung cancer patients. Current Opinion in Oncology 1996;8:126-132.

54. Smith TJ*, Hillner BE, Schmitz N, Linch DC, Dreger P, Goldstone AH, Boogaerts MA, Ferrant A, Link H, Zander A, Yanovich S, Kitchin R, Erder MH. Economic. Analysis of a Randomized Clinical Trial to Compare Filgrastim-Mobilized Peripheral Blood Progenitor Cell Transplantation and Autologous Bone Marrow Transplantation in Patients with Hodgkin and Non-Hodgkin Lymphoma. J Clinical Oncol 1997;15:5-10.

55. Bennett C, Smith T, Weeks J, Bredt J, Feinglass J, Fettting J, Hillner B, Somerfield M, Winn R. Use of hematopoietic colony stimulating factors: the American Society of Clinical Oncology Survey. J Clin Oncol 1996;14:2511-2520.

56. National Work Group on Literacy and Health (core member). Report of the National Work Group on Literacy and Health: suggestions for clinical practice and research. J Family Practice 1998;46:168-176.

57. Smith TJ. Lessons from living among the dying. Journal of Pastoral Care 1997;51:237-240.

58. ASCO Tumor Marker Expert Panel (manuscript editor). Clinical practice guidelines for the use of tumor markers in breast and colorectal cancer. J Clin Oncol 1996; 14:2843-2877.

59. Hillner BE, Kirkwood JM, Atkins MB, Johnson ER, Smith TJ. Economic Analysis of Adjuvant Interferon-alpha B in High Risk Malignant Melanoma. J Clin Oncol 1997;15:2351-2358.

60. Hillner BE, McDonald MK, Desch CE, Smith TJ, Penberthy LT, Maddox P, Retchin SM. Costs of care associated with non small cell lung cancer in a commercially insured cohort. Journal of Clinical Oncology 1998;16:1420-1424.

61. Morrison SE, Meier DE, Cassel CK. [Smith TJ, Discussant, Clinical Problem- Solving] When too much is too little. N Engl J Med 1996;335:1755-60.

62. Smith TJ*, Hillner BE, Mitchell RB. Editorial. Decision analysis in non-small cell lung cancer: not back to the drawing modeling board, back to the bedside. J Clin Oncol 1997;15:870-872.

63. Breast cancer surveillance expert panel (panel member, manuscript editor). Recommended breast cancer surveillance guidelines. J Clin Oncol 1997;15:2149- 2156.

64. Milanese S, Hansen LA, Desch CE, Honeycutt C, Tesfaye F, Smith TJ*. Impact of histamine and histamine-2 receptor antagonists on quality of life and anti-tumor response: results of a pilot trial. European J Cancer 1998;33(14):2436-2437.

65. Smith TJ, Desch CE, Hackney MH, Shaw JE. How long does it take to get a Ado not resuscitate order”? J Palliat Care 1997;13:5-8.

66. Update of ASCO clinical practice guidelines for hematopoeitic growth factors, 1997. (Manuscript editor) Journal of Clinical Oncology, in press.

67. ASCO Non-small cell lung cancer expert panel. Clinical practice guidelines for the treatment of unresectable non-small-cell lung cancer. J Clinical Oncology 1997; 15:2996-3018.

68. *Smith TJ, Somerfield MR. The ASCO experience with evidence-based clinical practice guidelines. Oncology 1997;11(Suppl 9):1-5.

69. *Smith TJ, Bear HD. (Editorial) Colorectal cancer follow up: making guidelines based on the evidence. Gastroenterology 1998;114:211-213.

70. *Smith TJ, Mitchell RB. (Editorial) The Mather Article Reviewed: Economic and clinical analysis of lung cancer treatments. Oncology 1998;12:210-216.

71. *Smith TJ, Swisher K, Ulmer D, Mitchell RB, Colley LJ. A randomized clinical trial to involve cancer patients in decisions about palliative chemotherapy and radiation therapy by Apatient indemnification”: reasons for failure of the trial. Submitted.

72. Bast R, Desch CE, Hayes DF, Kemeny NE, Ravdin P, Somerfield MR, Smith TJ [manuscript editor]. 1997 Update of recommendations for the use of tumor markers in breast and colorectal cancer: report of the American Society of Clinical Oncology Expert Panel. J Clin Oncol 1998; 16:793-5.

73. Bloomfield DJ, Krahn MD, Neogi T, Panzarella T, Smith TJ, Warde P, Willan AR, Ernst S, Moore MJ, Neville A, Tannock IF. Economic evaluation of chemotherapy with mitoxantrone plus prednisone for symptomatic hormone resistant prostate cancer, based on a Canadian randomized trial with palliative endpoints. J Clin Oncol 1998, 16:2272 -2279.

74. Brown ML, Glick HA, Harrell FE, Herndon JE, McCabe MS, Moinpour CM, Schulman K, Smith TH, Weeks JC, Seils DM. Integrating economic analysis into cancer clinical trials: the NCI-ASCO Economics Workbook. J Natl Cancer Institute Monographs 1998;24:1-28.

75. *Smith TJ, Somerfield MJ, Desch CE, David M. Would oncologists want chemotherapy if they had non-small cell lung cancer? Results of a 1997 survey. Oncology 1998;12:360-65.

76. Desch CE, Grasso M, McCue M, Buonaiuto D, Grasso K, Smith TJ.* A rural cancer outreach program lowers patient care costs and benefits both the rural hospitals and sponsoring academic medical center. J Rural Health, 1999;15:157-167.

77. *Smith TJ, Schnipper LJ. The American Society of Clinical Oncology Program to Improve End of Life Care. J Palliative Medicine 1998;1:221-230.

78. Hillner BE, Smith TJ. [Editorial] When does a clinical trial warrant an economic analysis?. JNCI 1998;90:724-5.

79. *Smith TJ, Swisher K. [Editorial] Telling cancer patients the truth: why we should, why we don’t, and why it matters. JAMA 1998;279:1746-1748.

80. American Society of Clinical Oncology Task Force on End of Life Care. [Panel member, editor of sections on Economic Barriers, Elements of Quality of Care] Cancer care during the last phase of life. J Clin Oncol 1998;16:1986-96.

81. Penberthy L, Retchin SM, McDonald MK, McClish DK, Desch CE, Smith TJ, Hillner BE, Newschaffer CJ. Predictors of Medicare costs in elderly beneficiaries with breast, colorectal, lung, or prostate cancer. Health Care Manag Sci 1999;2:149-60.

82. *Smith TJ. Health service studies in the terminally ill patient. Cancer Treat Res 1998;97:81-97.

83. Hillner BE, McDonald MK, Desch CE, Smith TJ, Penberthy LT, Retchin SM. A comparison of patterns of care of nonsmall cell lung carcinoma patients in a younger and Medigap Commercially insured cohort. Cancer 1998;83:1930-7.

84. Hillner BE, Smith TJ (editorial). Hospital volume and patient outcomes in major cancer surgery: a catalyst for quality assessment and concentration of cancer services. JAMA 1998;280:1783-4.

85. Desch CE, Penberthy LT, Hillner BE, McDonald MK, Smith TJ, Pozez AL, RetchinSM. A sociodemographic and economic comparison of breast reconstruction, mastectomy, and conservative surgery. Surgery, 1999;125:441-447.

86. Hillner BE, Smith TJ, Desch CE. Hospital and physician volume or specialization and outcome in cancer treatment. Journal of Clinical Oncology 2000;18:2327-2340.

87. Somerfield MR, Stefanek ME, Smith TJ. A systems model for adaptation to somatic distress among cancer survivors. Psycho-oncology, 1999, 8:334-343.

88. *Smith TJ, Davidson NE, Schapira DV, Grunfeld E, et al. American Society of Clinical Oncology 1998 Update of Recommended Breast Cancer Surveillance Guidelines. J Clinical Oncology 1999;17:1080-82.

89. *Smith TJ, Hillner BE. Clodronate reduced the incidence of bony and visceral metastases in patients with breast cancer and tumor cells in the bone marrow Evidence-Based Medicine 1999;4:43.

90. Smith TJ, Hillner BE. Tamoxifen should be cost-effective in reducing breast cancer risks in high-risk women. Journal of Clinical Oncology 2000, 18:284-286.

91. Bennett CL, Weeks JA, Somerfield MR, Feinglass J, Smith TJ. Use of Hematopoietic Colony Stimulating Factors: Comparison of the 1994 and 1997 American Society of Clinical Oncology Surveys Regarding ASCO Clinical Practice Guidelines. Journal of Clinical Oncology, 1999,17: 1-6.

92. Arthur DW, Schmidt-Ullrich RK, Friedman RB, Wazer DE, Kachnic LA, Amir C, Bear HD, Hackney MH, Smith TJ, Lawrence W. Accelerated Superfractionated Radiotherapy for Inflammatory Breast Carcinoma: Complete Response Predicts Outcome and Allows for Breast Conservation. Int. J. Radiation Oncology Biol. Phys., 1999, 44:289-296.

93. Bennett CL, Bishop MR, Tallman MS, Somerfield MR, Feinglass J, Smith TJ. for the Health Services Research Committee of the American Society of Clinical Oncology. The association between physician reimbursement in the US and use of hematopoeitic colony stimulating factors as adjunct therapy for older patients with acute myeloid leukemia: Results from the 1997 American Society of Clinical Oncology survey. Annals of Oncology, 1999, 10:1355-1359.

94. Hillner BE, Weeks JC, Smith TJ, Desch CE. Pamidronate in prevention of bone complications in metastatic breast cancer: a cost effectiveness analysis. Journal of Clinical Oncology, 2000, 18:72-79.

95. Smith TJ. Future strategies needed for palliative care. Seminars in Radiation Oncology, 2000, 10:254-261.

96. Smith TJ. Tell it like it is. Journal of Clinical Oncology, 2000, 18:3441-3445.

97. Ravdin P, Hayes DF, Bates S, Fritsche H, Jessup JM, Kemeny N, Locker GY, Mennel RG, Smith TJ Somerfield MR. 2000 update of recommendations for the use of tumor markers in breast and colorectal cancer. Journal of Clinical Oncology, 2001, 19:1865-1878.

98. Desch CE, Benson AB, Flynn PJ, Krause Loprinzi CL, Minsky BD, Petrelli NJ, Pfister DG, Smith TJ, Somerfield MR. 2000 Update of ASCO Colorectal Cancer Surveillance Guidelines. Journal of Clinical Oncology, 2000, 18:3586-3588.

99. Ozer H, Armitage JO, Bennett CL, Crawford J, Demetri GD, Pizzo PA, Schiffer CA, Smith TJ, Somlo G, Wade JC, Wade JL, Winn RJ, Wozniak AJ, Somerfeld MR. (ASCO Special Article) 2000 Update of Recommendations for the Use of Hematopoietic Colony-Stimulating Factors: Evidence-based, Clinical Practice Guidelines. Journal of Clinical Oncology, 2000, 18:3558-3585.

100. Smith TJ, Girtman J, Riggins J. Why Academic Divisions of Hematology/Oncology Are in Trouble and Some Suggestions for Resolution. Journal of Clinical Oncology, 2001, 19:260-264.

101. *Smith TJ, Hillner BE. Ensuring Quality Cancer Care by the Use of Clinical Practice Guidelines and Critical Pathways. J Clin Oncol 2001 19: 2886-2897.

102. Smith TJ, Penberthy L, Hillner BE, Desch CE, Retchin S. Hospice utilization by Medicare beneficiaries in Virginia. Submitted.

103. Charles L. Loprinzi, Daniel Hayes, and Tom Smith. Doc, Shouldn’t We Be Getting Some Tests? J Clin Oncol 2000 18: 2345-2348

104. Lyckholm LJ, Hackney MH, Smith TJ. Ethics of rural health care. Critical Reviews in Oncology/Hematology, 2001 40:131-138.

105. Coyne P, Ramakrishnan V, Smith TJ. Nebulized fentanyl improves patients’ perception of breathing, respiratory rate, and oxygen saturation in dyspnea. J Pain Symptom Management, 2002 23: 157-60.

106. Neff P, Lyckholm L, Smith T. Truth or consequences: what to do when the patient doesn’t want to know. J Clin Oncol 2002;20:3035-3037.

107. Payne SK, Coyne P, Smith TJ. The health economics of palliative care. Oncology (Huntingdon) 2002;16:801-808.

108. Smith TJ, Staats PJ, Pool G, Coyne P, et al. Randomized clinical trial of comprehensive medical management of refractory cancer pain vs. comprehensive medical management plus intrathecal implantable drug delivery systems. Journal of Clinical Oncology 2002; 20: 4040-9

109. Quillin JM, Boardman CH, Bodurtha J, Smith T. Preventive gynecologic surgery for BRCA1/2 carriers--information for decision-making. Gynecol Oncol. 2003 Oct;83(1):168-70

110. Smith T. Adding hospice and palliative care services to the cancer center

menu. J Palliat Med 2003;6:641-644.

111. Smith TJ, Cassel JB, Coyne PS, Hager MA. A high-volume specialist palliative care unit and team may reduce in-hospital end-of-life care costs. J Pall Medicine 2003;6:699-705.

112. Smith TJ. Medically appropriate follow up of the patient with lung cancer: an evidence based approach. Seminars in Oncology, June 2003:30;361-368.

113. Smith TJ, Coyne P, Staats P. Implantable drug delivery systems: what is the evidence? Supportive Cancer Therapy 2004:1:1-5.

114. Smith TJ, Coyne P. How to use implantable intrathecal drug delivery systems for refractory cancer pain. J Supportive Oncology 2003:1:1-4.

115. Smith TJ, Hillner BE, Bear HD. Taking action on the volume-quality relationship: How long can we hide our heads in the colostomy bag? J Natl Cancer Inst 2003;95:695-8. (Invited editorial.)

116. Smith TJ. We can reduce the cost of in-hospital end of life care. Oncology Times 2003;225(11):4-6.

117. Penberthy L, McClish D, Manning C, Retchin S, Smith TJ. The Added Value of Claims for Cancer Surveillance: Results of Varying Case Definitions. Med Care. 2005 Jul;43(7):705-12.

118. French, W., Coyne, P., and Smith, T., "Peer Viewpoint: Management of Dyspnea."  Journal of Supportive Oncology.   Vol. 1 No. 1, May/June 2003 pp. 28-29.

119. Smith TJ, Swainey C, Coyne PJ. Pain Management, including Intrathecal Pumps. Current Oncology Reports,.Curr Oncol Rep. 2004 Jul;6(4):291-6.

120. Coyne, P. J., Hansen, L., Laird, J., Buster, P. and Smith, T., "Massive Hydromorphone Dose Delivered Subcutaneously Instead of Intrathecally : Guidelines for Prevention and Management of Opioid, Local Anesthetic and Clonidine Overdose."  Journal of Pain and Symptom Management . Vol 28/3 pp 273-276

121. Loblaw DA, Mendelson DS, Talcott JA, Virgo KS, Somerfield MR, Ben-Josef E, Middleton R, Porterfield H, Sharp SA, Smith TJ, Taplin ME, Vogelzang NJ, Wade JL Jr, Bennett CL, Scher HI; American Society of Clinical Oncology. American Society of Clinical Oncology Recommendations for the Initial Hormonal Management of Androgen-Sensitive Metastatic, Recurrent, or Progressive Prostate Cancer. JCO Jul 15 2004: 2927-2941.

122. Webb-Wright J, Sacks TE, Smith TJ. The Cherny article reviewed. Oncology 18(12): 18-19, 2004.

123. Smith T, Coyne PJ, for the Cancer Pain Trial investigators. Implantable drug delivery systems (IDDS) after failure of comprehensive medical management (CMM) can palliate symptoms in the most refractory cancer pain patients. J Pall Medicine 8(4):736-42, 2005.

124. Smith TJ, Coyne PJ, Smith WR, Roberts JD, Smith VS. Use of an Implantable Drug Delivery System for Refractory Chronic Sickle Cell Pain. Am J Hematology 2005 Feb;78(2):153-4.

125. Smith TJ, Staats PJ, Pool G, Coyne P, et al. Intrathecal implantable drug delivery systems give sustained pain control, less side effects, and possibly better survival for six months: results of a randomized clinical trial vs. comprehensive medical management. Ann Oncol. 2005 May;16(5):825-33. Epub 2005 Apr 7.

126. Smith TJ. The American Society of Clinical Oncology Recommended Breast Cancer Surveillance Guidelines can be done in a routine office visit. J Clin Oncol. 2005 Sep 20;23(27):6807

127. Smith TJ, Khatcheressian J. Review: chemotherapy and hormonal therapy reduce recurrence and mortality at 15 years in early breast cancer. ACP J Club. 2005 Nov-Dec;143(3):58.

128. Khatcheressian J, Cassel JB, Lyckholm L, Coyne P, Hagenmueller A, Smith TJ. Improving palliative and supportive care in cancer patients. Oncology (Williston Park). 2005 Sep;19(10):1365-76; discussion 1377-8, 1381-2, 1384 passim.

129. Coyne PJ, Smith T, Laird J, Hansen LA, Drake D. Effectively starting and titrating intrathecal analgesic therapy in patients with refractory cancer pain. Clin J Oncol Nurs. 2005 Oct;9(5):581-3. Review.

130. Smith TJ, Swainey C, Coyne PJ. Pain management, including intrathecal pumps. Curr Pain Headache Rep. 2005 Aug;9(4):243-8. Review.

131. Khatcheressian JL, Smith TJ. (Ed) Randomized Trial of Long-Term Follow-Up for Early-Stage Breast Cancer: A Comparison of Family Physician Versus Specialist Care. J Clin Oncol. 2006;24:1-3.

132. Smith TJ, Khatcheressian J. Review: chemotherapy and hormonal therapy reduce recurrence and mortality at 15 years in early breast cancer. ACP J Club. 2005 Nov-Dec;143(3):58. No abstract available.

133. Smith T, Khatcheressian J, Lyman G, Ozer H, et al. 2006 ASCO recommendations for the use of white blood cell growth factors. J Clin Onc 2006;24:1-19.

134. Matsuyama R, Reddy SN, Smith TJ. Why do patients choose chemotherapy near the end of life? A review of the perspective of those facing death from cancer. J Clin Oncol. 2006 Jul 20;24(21):3490-6. Review.

135. Khatcheressian JL, Wolff AC, Smith TJ, GrunfeldE, Muss HB, Vogel VG III, Halberg F, Somerfield MR, Davidson NE, American Society of Clinical Oncology 2006 Update of the Breast Cancer Follow-up and Management Guideline in the Adjuvant Setting. J Clin Oncol. 2006 Nov 1;24(31):5091-7. Epub 2006 Oct 10.

136. White K, Stover KG, Cassel JB, Smith TJ. Nonclinical outcome of hospital based palliative care. Journal of Healthcare Management 2006;51:253-265.

137. Khatcheressian J, Smith T. Practice changing implications today, compelling data for tomorrow. Palliative and Supportive Care (eds). Oncology 2006; 20: 43-8.

138. Kracen AC, Matsuyama R, Reddy S, & Smith T. (2006). Non-small cell lung cancer: A patient’s end of life decision to pursue chemotherapy. The American Journal of Hematology/Oncology, 5, 687-690.

139. Sterling RK, Lyons CD, Stravitz RT, Luketic VA, Sanyal AJ, Carr ME, Smith TJ, Hackney MH, Contos MJ, Mills SA, Kuhn JG, Nolte ME, Shiffman ML. Percutaneous liver biopsy in adult haemophiliacs with hepatitis C virus: safety of outpatient procedure and impact of human immunodeficiency virus coinfection on the spectrum of liver disease. Haemophilia. 2007 Mar;13(2):164-71.

140. Hillner BE, Smith TJ. Do the large benefits justify the large costs of adjuvant breast cancer trastuzumab? J Clin Oncol. 2007 Feb 20;25(6):611-3.

141. Kelso CM, Lyckholm LJ, Coyne PJ, Smith TJ. Palliative care consultation in the process of organ donation after cardiac death. J Palliat Med. 2007 Feb;10(1):118-26. Review.

142. Lingerfelt BM, Swainey CW, Smith TJ, Coyne PJ. Nebulized lidocaine for intractable cough near the end of life. J Support Oncol. 2007 Jul-Aug;5(7):301-2

143. Youssef JA, Lyckholm LJ, Smith TJ, Shickle L, Parker GG, Matsuyama RK. A comparison of hematology/oncology clinic attendance between insured and underinsured patients at an urban academic hospital: Identifying barriers and ways to overcome them. Supp Oncol. 2006;4:435-Abstract PA-16. Available from: . Accessed 02/15/07.

144. Matsuyama, RK, Grange, C, Lyckholm LJ, Utsey SO, Smith TJ. Cultural Perceptions in Cancer Care among African-American and Caucasian Patients. Jrnl Ntl Med Assoc . 2007; 99(10): 1113-1119

145. Grange C, Matsuyama RK, Ingram K, Lyckholm LJ, Smith TJ. Identifying supportive and unsupportive responses of others: Perspectives of African-American and caucasian cancer patients. J Psychosoc Oncol. in press.

146. Loblaw DA, Virgo KS, Nam R, Somerfield MR, Ben-Josef E, Mendelson DS, Middleton R, Sharp SA, Smith TJ, Talcott J, Taplin M, Vogelzang NJ, Wade JL 3rd, Bennett CL, Scher HI; American Society of Clinical Oncology. Initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer: 2006 update of an American Society of Clinical Oncology practice guideline. J Clin Oncol. 2007 Apr 20;25(12):1596-605. Epub 2007 Apr 2. Review.

2. Abstracts (no longer put in c.v.)

3. Books/Chapters

1. *Smith T, Hansen LA: "Antineoplastic Therapy", in Ornato JP and Gonzalez ER. (eds): Handbook of Pharmacotherapeutics in Emergency Medicine, Churchill Livingstone, New York, 1990

2. *Smith TJ, Desch CE, Hillner BE. "Analysis of Economic Issues" in High Dose Cancer Therapy: Pharmacology, Hemopoietins, and Stem Cells, (eds) Antman K, Armitage JO. Williams and Wilkins, Baltimore MD. 1992.

3. Desch CE, Smith TJ*. Breast Cancer Diagnosis and Treatment Update: 1993 and Beyond. American Health Consultants, Atlanta, Georgia, 1993.

4. Bennett CL, Hillner BE, Smith TJ*. "Economic Analysis of Cancer Care" in Abeloff MA, Armitage JO, Lichter AS, Neiderhuber JE (eds) Clinical Oncology Churchill Livingstone, 1994.

5. *Smith TJ, Hillner BE, Desch CE. High dose chemotherapy for breast cancer: efficacy, cost, and cost-effectiveness. in American Society of Clinical Oncology Educational Book, Chicago, Illinois. p 86-91.

6. Hillner BE, Smith TJ. Methods of developing clinical practice guidelines. in American Society of Clinical Oncology Educational Book, Chicago, Illinois. p 261-265.

7. Bennett CL, Smith TJ, Gulati SC, Armitage JL. A Health Policy Perspective on High-Dose Cancer Therapy: Cost, Effectiveness, and Cost-effectiveness. in Armitage JO, Antman KH. High-Dose Cancer Therapy: Pharmacology, Hematopoietins, Stem Cells. 2nd Edition, William and Wilkins, Baltimore, MD 1995.

8. Brown P, Mettger W, Friedell G, Smith TJ. Incorporating Literacy into Research and Practice. In Cancer and Literacy. JNCI Monograph, Bethesda, MD, 1995.

9. Hillner BE, Smith TJ. A short review of cost-effectiveness analysis of oncologic treatments. In Hillman AL, Champey Y, Schwartz JS (eds) The Challenges in Studying the Socioeconomic Dimensions in Cancer Therapy. The Medicine Group, Yardley, PA, 1995.

10. Loprinzi CL, Smith TJ*. Surveillance testing in curatively-treated cancer survivors. ASCO Educational Symposium, Fall 1996 Education Book, ASCO, Alexandria, VA.

11. Smith TJ, Yanovich S, Hillner BE. Costs of high dose chemotherapy and blood/marrow stem cell transplantation. In Lister J, Ball T. Bone Marrow Transplantation. Churchill Livingstone, in press.

12. Smith TJ. Health service studies in the terminally ill cancer patient. In Bennett CL (ed) Cancer Policy, Kluwer Academic Publishers. 1998.

13. Smith TJ. End of life care: preserving quality and quantity of life in managed care. In Perry MC (Ed) American Society of Clinical Oncology Educational Book, American Society of Clinical Oncology, Alexandria, VA, 1997. pp 303-307.

14. Smith TJ. Health care economics of palliative therapy. Springer Verlag, Tokyo, in press, 1998.

15. Bennett CL, Hillner BE, Smith TJ. "Economic Analysis of Cancer Care" in Abeloff MA, Armitage JO, Lichter AS, Neiderhuber JE (eds) Clinical Oncology 2nd Edition, Churchill Livingstone, 2000.

16. Lyckholm LL,*Smith TJ. Economic outcomes and palliative care. In Bruera E, Portenoy RK (eds) Topics in Palliative Care, Oxford University Press, 2001.

17. Smith TJ. The role of G and GM-CSF in clinical practice. In American Society of Clinical Oncology 1999 Educational Book, Alexandria, VA. 1999.

18. Lyckholm LL,*Smith TJ. Allocation of cancer care resources by effectiveness and cost effectiveness. In, National Cancer Control Programmes; Policies and Managerial Guidelines. WHO, in press.

19. Smith TJ. Designing model health care systems to provide cost-effective care. In Cancer Survivorship Throughout the Life Span. New Jersey Commission on Cancer Research.

20. Hackney MH, Lyckholm L, Simonson CJ, Smith TJ*. Ethics of rural health care. For Cancer Research and Treatment, Geneva, Switzerland, 1999.

21. Smith TJ, Staats P, Catala E, Pousa L, Pericai E, Buchser E, Perey L. Randomized comparison of Medtronic intrathecal drug delivery systems (IDDS) plus comprehensive medical management (CMM) vs. CMM for unrelieved cancer pain, Hamburg, Germany, 2000 (Annals of Oncology, 11:145, 2000).

22. Hackney MH, Simonson CJ, Overmeyer K, Brigle K, Cragg L, Shaw J, Sismanis A, Lyckholm L and Smith TJ. Cancer Education through a Rural Cancer Outreach Program. American and European Association of Cancer Education Joint Meeting, November 2-5, 2000, Washington, DC (Journal of Cancer Education - Supplement to Vol 15, 2000)

23. Thomas J. Smith, M.D. "The Usefulness of Utility in Making in Decisions About Palliative Care," in Portenoy R (ed) "Proceedings of the NIH Conference on Palliative Care Research: Issues in Palliative Care Research." In press, 2002

24. Smith TJ, Heddinger S. Medically appropriate Follow up of the patient with breast and lung cancer: evidence based approach. ASCO Educational Book, 2002.

25. Smith TJ. Cost in palliative care. Panke,J. T. & Coyne, P. (2003) Conversations in Palliative Care. Pensacola,FL: Pohl Publishing.

26. Lunney G, Foley KM, Smith TJ, Gelband H. Describing Death in America: What We Need to Know. National Academies Press, Washington DC. 2003.

27. Khatcheressian J, Smith T. Economics of Cancer Care. In “Oncology, and evidence based approach.” Springer, 2006.

28. Cassel JB, Smith T. “Cost avoidance and other financial outcomes for palliative care programs” in Bruera E, Higginson I, Ripamonti C, vonGunten C. Textbook of Palliative Care. Hodder Arnold, 2006.

4. Other - reviews, exhibits, films, tapes, etc.

1. Smith T: The Use of Conditional Discriminators in a Medical Audit. Medical doctorate thesis, Yale University School of Medicine, 1979.

................
................

In order to avoid copyright disputes, this page is only a partial summary.

Google Online Preview   Download